• V Pengo, A Banzato, E Bison, G Zoppellaro, S Padayattil Jose, and G Denas.
• Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padova School of Medicine, Padova, Italy vittorio.pengo@unipd.it.
• Lupus. 2016 Mar 1; 25 (3): 301-6.

BackgroundNew oral anticoagulants may simplify long-term therapy in conditions requiring anticoagulation. Rivaroxaban is a direct factor Xa inhibitor that has been extensively studied and is now approved for the prevention and therapy of a number of thromboembolic conditions.Objective And MethodsThis is a multicentre, randomized, open-label, study that will evaluate if Rivaroxaban 20 mg od (or 15 mg od in patients with moderate renal insufficiency) is non-inferior to warfarin (INR target 2.5), for the prevention of thromboembolic events, major bleeding and death in high risk (triple positive) patients with antiphospholipid syndrome. Secondary endpoints will assess the incidence of any individual component of the composite end point. An external adjudication committee will evaluate all suspected outcome events. This will be a unique trial, as it will enrol the biggest homogenous cohort of high risk APS individuals.ConclusionThe methods and the study design should be appropriate to achieve study results that are both scientifically valid and relevant to clinical practice.© The Author(s) 2015.

44 keywords...

hide…